297 related articles for article (PubMed ID: 23789844)
21. Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1.
Lin JH; Lin JY; Chou YC; Chen MR; Yeh TH; Lin CW; Lin SJ; Tsai CH
Blood; 2015 Apr; 125(14):2228-38. PubMed ID: 25631773
[TBL] [Abstract][Full Text] [Related]
22. Adenosine signaling inhibits CIITA-mediated MHC class II transactivation in lung fibroblast cells.
Fang M; Xia J; Wu X; Kong H; Wang H; Xie W; Xu Y
Eur J Immunol; 2013 Aug; 43(8):2162-73. PubMed ID: 23681904
[TBL] [Abstract][Full Text] [Related]
23. Notch1-mediated signaling induces MHC class II expression through activation of class II transactivator promoter III in mast cells.
Nakano N; Nishiyama C; Yagita H; Koyanagi A; Ogawa H; Okumura K
J Biol Chem; 2011 Apr; 286(14):12042-8. PubMed ID: 21321116
[TBL] [Abstract][Full Text] [Related]
24. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines.
Tschickardt ME; Lu Y; Jacim M; Ussery GD; Steimle V; Mach B; Blanck G
Int J Cancer; 1995 Aug; 62(4):461-5. PubMed ID: 7635572
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells.
Morimoto Y; Toyota M; Satoh A; Murai M; Mita H; Suzuki H; Takamura Y; Ikeda H; Ishida T; Sato N; Tokino T; Imai K
Br J Cancer; 2004 Feb; 90(4):844-52. PubMed ID: 14970863
[TBL] [Abstract][Full Text] [Related]
26. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.
Smith MA; Wright G; Wu J; Tailor P; Ozato K; Chen X; Wei S; Piskurich JF; Ting JP; Wright KL
J Biol Chem; 2011 Mar; 286(10):7893-7904. PubMed ID: 21216962
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
28. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III.
Holling TM; van der Stoep N; Quinten E; van den Elsen PJ
J Immunol; 2002 Jan; 168(2):763-70. PubMed ID: 11777970
[TBL] [Abstract][Full Text] [Related]
29. The major histocompatibility complex class II transactivator is differentially regulated by interferon-gamma and transforming growth factor-beta in microglial cells.
Pazmany T; Tomasi TB
J Neuroimmunol; 2006 Mar; 172(1-2):18-26. PubMed ID: 16360884
[TBL] [Abstract][Full Text] [Related]
30. MHC class II transactivator represses human IL-4 gene transcription by interruption of promoter binding with CBP/p300, STAT6 and NFAT1 via histone hypoacetylation.
Zhou X; Jiang Y; Lu L; Ding Q; Jiao Z; Zhou Y; Xin L; Chou KY
Immunology; 2007 Dec; 122(4):476-85. PubMed ID: 17645498
[TBL] [Abstract][Full Text] [Related]
31. CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells.
Londhe P; Zhu B; Abraham J; Keller C; Davie J
Int J Cancer; 2012 Aug; 131(4):E437-48. PubMed ID: 21989738
[TBL] [Abstract][Full Text] [Related]
32. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
34. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
Rohn W; Tang LP; Dong Y; Benveniste EN
J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7.
Nie K; Zhang T; Allawi H; Gomez M; Liu Y; Chadburn A; Wang YL; Knowles DM; Tam W
Am J Pathol; 2010 Sep; 177(3):1470-9. PubMed ID: 20651244
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.
Moribe F; Nishikori M; Takashima T; Taniyama D; Onishi N; Arima H; Sasanuma H; Akagawa R; Elloumi F; Takeda S; Pommier Y; Morii E; Takaori-Kondo A; Murai J
PLoS One; 2021; 16(1):e0237554. PubMed ID: 33513156
[TBL] [Abstract][Full Text] [Related]
37. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.
LeibundGut-Landmann S; Waldburger JM; Krawczyk M; Otten LA; Suter T; Fontana A; Acha-Orbea H; Reith W
Eur J Immunol; 2004 Jun; 34(6):1513-25. PubMed ID: 15162420
[TBL] [Abstract][Full Text] [Related]
38.
Sengupta S; Naz S; Das I; Ahad A; Padhi A; Naik SK; Ganguli G; Pattanaik KP; Raghav SK; Nandicoori VK; Sonawane A
J Biol Chem; 2017 Apr; 292(17):6855-6868. PubMed ID: 28209712
[No Abstract] [Full Text] [Related]
39. Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression.
Murphy SP; Tomasi TB
Mol Reprod Dev; 1998 Sep; 51(1):1-12. PubMed ID: 9712312
[TBL] [Abstract][Full Text] [Related]
40. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
